Evidence map›Paper›PMID 33941385›Full record

ArticleSeminars in arthritis and rheumatism2021

Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group.

Amy Fuller, Ken Cai, Georgios Filippou, Tristan Pascart, Cesar Diaz-Torne, Owen Hensey, David Grossberg, Robin Christensen, Beverley Shea, Jasvinder A Singh and 3 more

Open access · greenAbstract read
In one paragraph

Article in Seminars in arthritis and rheumatism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review: Outcome measures in calcium pyrophosphate deposition.Best practice & research. Clinical rheumatology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 9 countries.

Amy FullerAcademic Rheumatology, University of Nottingham, Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK. Electronic address: amy.fuller@nottingham.ac.uk.
Ken CaiBone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Georgios FilippouRheumatology Unit, ASST-Fatebenefratelli L, Sacco University Hospital, University of Milan, Italy.
Tristan PascartDepartment of Rheumatology, Hopital Saint-Philibert, Lille Catholic University, Lille, France.
Cesar Diaz-TorneDepartment of Rheumatology, Hospital de la Santa Creu i Sant Pau, Universitat Autonòma de Barcelona, Spain.
Owen HenseyThe Central Remedial Clinic, Dublin, Ireland.
David GrossbergHoly Cross Hospital, Silver Spring, MD, USA; Suburban Hospital, Bethesda, MD, USA.
Robin ChristensenDepartment of Clinical Research, Copenhagen and Research Unit of Rheumatology, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Southern Denmark, Odense University Hospital, Denmark.
Beverley SheaOttawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Jasvinder A SinghMedicine Service, VA Medical Center, Birmingham, AL, USA; Department of Medicine at the School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA; Department of Epidemiology at the UAB School of Public Health, Birmingham, AL, USA.
Sara K TedeschiDivision of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Nicola DalbethBone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Abhishek AbhishekAcademic Rheumatology, University of Nottingham, Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK.
University of Auckland · NZUniversity of Nottingham · GBBirmingham VA Medical Center · USBrigham and Women's Hospital · USCentral Remedial Clinic · IEHôpital Saint-Philibert · FRHospital de Sant Pau · ESOttawa Hospital · CASuburban Hospital · USUniversity of Milan · ITUniversity of Southern Denmark · DK

Funding

Studying pseudogout using naturallanguage processing and novelimaging approachesK23AR075070 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI TEDESCHI, SARA K. · 2019 to 2023
$937k
NIAMS NIH HHS K23 AR075070NIAMS NIH HHS L30 AR070514
6 · The paper itself

Abstract

objectiveTo explore the lived experience of people with calcium pyrophosphate deposition (CPPD) disease and the impact of this condition on their daily lives.

methodsPatients with CPPD and their caregivers were invited to take part in a one-to-one (patient only) or paired (patient and caregiver) semi-structured interview. Interviews covered patients' diagnosis and treatment experiences, and the impact of CPPD on their daily lives. Transcribed interviews were analysed using inductive thematic analysis.

results28 patient interviews, six of which included a caregiver, were conducted across five countries. Acute CPP crystal arthritis flares resulted in temporary but profound disability for most patients, disrupting their ability to go about day-to-day activities, and they sought immediate medical attention. CPPD+OA and chronic CPP crystal inflammatory arthritis presented patients with longer term limitations in daily lives. Patients and their caregivers described these disruptions and limitations, which included a reduced ability or inability to complete household and self-care tasks, exercise, socialise, work and drive. They also described how arthritis pain and resulting limitations adversely impacted upon patients' psychological wellbeing. Delays in referral to specialists and diagnostic uncertainty were described by many. Lack of appropriate treatment or access to treatments only upon worsening of symptoms impacted upon the length of time some patients spent in pain and with functional limitations.

conclusionThis study is the first to demonstrate the wide-ranging impact of CPPD, and highlights the need for improved diagnosis, physician training, as well as greater emphasis upon finding targeted therapies to specifically treat CPPD.

Indexed as

CalcinosisChondrocalcinosisCalcium PyrophosphateCaregiversDiphosphatesHumansCalcium PyrophosphateDiphosphatesCPPDImpact, QualitativeLived experienceOMERACT

Identifiers

PMID33941385
PMCPMC10061547
OpenAlexW3154631613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.